导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.02% | 2822/4773 |
| 近一周 | -2.19% | 1449/5462 |
| 近一月 | -4.17% | 2270/5421 |
| 近一季 | -7.52% | 2434/5209 |
| 近半年 | -2.92% | 2065/4920 |
| 近一年 | 0.55% | 2542/4366 |
| 近两年 | 45.39% | 1628/2954 |
| 近三年 | 27.67% | 1151/2253 |
| 成立以来 | 75.63% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.58% 3289/4961 |
12.09% 2236/5312 |
- - |
- - |
| 2025 | 19.87% 2172/4813 |
-0.92% 2466/3635 |
2.22% 1736/4076 |
18.02% 2366/4524 |
0.28% 2081/4813 |
| 2024 | 16.82% 759/3463 |
2.86% 684/2808 |
-1.20% 979/3014 |
16.81% 1342/3129 |
-1.59% 1762/3463 |
| 2023 | -8.99% 1081/2656 |
4.26% 1003/2280 |
-3.86% 930/2385 |
-2.91% 785/2515 |
-6.49% 1798/2655 |
| 2022 | -19.20% 815/2207 |
-13.92% 873/1919 |
6.82% 598/2016 |
-13.66% 942/2113 |
1.77% 1150/2208 |
| 2021 | -3.28% 897/1822 |
-3.00% 740/1255 |
4.17% 914/1330 |
-5.66% 841/1466 |
1.47% 921/1822 |
| 2020 | 27.73% 573/1250 |
-9.58% 691/1028 |
13.36% 625/1067 |
10.47% 547/1164 |
12.79% 434/1184 |
| 2019 | 35.85% 367/1092 |
26.51% 400/754 |
-0.31% 251/804 |
0.79% 467/850 |
6.88% 530/918 |
| 2018 | -22.60% 248/834 |
- - |
- - |
- - |
-11.82% 356/691 |
| 2017 | 22.62% 146/714 |
- - |
- - |
- - |
- - |
| 2016 | -7.98% 235/605 |
- - |
- - |
- - |
- - |
| 2015 | 8.88% 165/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 2011 | - - |
- - |
- - |
- - |
- - |
| 2010 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏沪深300ETF联接A VS. 长安沪深300非周期A(740101) |